
    
      This study is to evaluate the efficacy (HbA1c change from baseline) and safety of ASP1941 in
      combination with pioglitazone in subjects with type 2 diabetes mellitus (T2DM) who have
      inadequate glycemic control with pioglitazone alone. The effects of ASP1941 are compared with
      those of placebo. Double blind period continues for 24 weeks followed by open period in each
      patient.
    
  